Boltz PBC has partnered with Excelra to train the ADMET models in its BoltzMol-1 system on curated GOSTAR data. The models act as an early triage layer, filtering unfavorable compounds before purchase or synthesis.
Read the story
VS Pharmtech is developing VS-101, a repositioned radiosensitizer that weakens cancer cells' DNA repair and aims to boost existing treatments at roughly one-fifth the original dose. Early Korean trial data and FDA-cleared Phase 2 plans have put the Seoul startup on a global licensing path.
OncoC4 reported Phase 1/2 results for cesalatamig monotherapy in PD-(L)1-resistant/refractory NSCLC, with a 33% objective response rate and 90% disease control rate at 10 mg/kg every three weeks. The data were presented at the SITC 2026 Annual Meeting in Phoenix.
ABEC has commercially launched the ATB-2100 Advanced Therapy Bioreactor, a single-use cell expansion platform it says supports cell growth from preclinical development through commercial manufacturing. The company says the system has demonstrated expansion of T-cells, iPSCs and MSCs.
NORROY Bioscience presented its radiopharmaceutical pipelines in eight Top Rated Oral Presentations and three e-posters at the EANM'26 congress in Vienna, spanning prostate cancer, renal cell carcinoma and other indications.
Harbour BioMed has appointed Vivian Feng as Senior Vice President, Head of External Collaboration, based in Shanghai and reporting to Chief Strategy Officer Mike Patten. Feng brings over 16 years of biotech and pharma business development experience, most recently at Fosun Pharma.
Dizal will present three oral and five poster presentations at the ASH 2026 Annual Meeting, covering golidocitinib in T-cell lymphoma and HLH, birelentinib in CLL/SLL, and first-time clinical data for GW5282 in relapsed or refractory non-Hodgkin lymphoma.
Illumina has been selected to provide whole-genome sequencing for the SG-INSIGHT study under Phase III of Singapore's National Precision Medicine programme, expected to include around 450,000 individuals. The company will perform the work at its Singapore genomics facility.
Initial Phase II JASPIS-01 results show clinical activity for dapolsertib monotherapy in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma patients who have exhausted standard options. The data will be presented in a poster session at the 2026 ASH Annual Meeting in New Orleans.
